2024-05-09 02:35:55 ET
Summary
- Neuronetics' share price dropped after reporting soft Q1 2024 results, with weak system sales undermining strong treatment demand.
- Neuronetics' losses remain relatively large, and the company's balance sheet provides it with limited flexibility.
- The stock may have further to fall if Neuronetics is not able to demonstrate a clear path to profitability in the coming quarters.
Neuronetics’ ( STIM ) share price collapsed after the company reported slightly soft Q1 2024 results. There wasn’t really anything in the earnings which warranted a large selloff, but as I previously suggested , the increase in Neuronetics’ share price in recent months wasn’t justified by fundamentals either....
Read the full article on Seeking Alpha
For further details see:
Neuronetics: Reality Set In